Anti-Rheumatics Market Report, Size, Share, Trends and Forecast 2024-2032

IMARC Group's report titled "𝐀𝐧𝐭𝐢-𝐑𝐡𝐞𝐮𝐦𝐚𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐛𝐲 𝐓𝐲𝐩𝐞 (𝐏𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐛𝐚𝐬𝐞𝐝 𝐃𝐫𝐮𝐠𝐬, 𝐎𝐯𝐞𝐫-𝐭𝐡𝐞-𝐂𝐨𝐮𝐧𝐭𝐞𝐫 𝐃𝐫𝐮𝐠𝐬), 𝐃𝐫𝐮𝐠 𝐂𝐥𝐚𝐬𝐬 (𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐌𝐨𝐝𝐢𝐟𝐲𝐢𝐧𝐠 𝐀𝐧𝐭𝐢-𝐑𝐡𝐞𝐮𝐦𝐚𝐭𝐢𝐜𝐬 𝐃𝐫𝐮𝐠𝐬 (𝐃𝐌𝐀𝐑𝐃'𝐬), 𝐍𝐨𝐧𝐬𝐭𝐞𝐫𝐨𝐢𝐝𝐚𝐥 𝐀𝐧𝐭𝐢-𝐈𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐨𝐫𝐲 𝐃𝐫𝐮𝐠𝐬 (𝐍𝐒𝐀𝐈𝐃'𝐬), 𝐂𝐨𝐫𝐭𝐢𝐜𝐨𝐬𝐭𝐞𝐫𝐨𝐢𝐝𝐬, 𝐔𝐫𝐢𝐜 𝐀𝐜𝐢𝐝 𝐃𝐫𝐮𝐠𝐬, 𝐚𝐧𝐝 𝐎𝐭𝐡𝐞𝐫𝐬), 𝐑𝐨𝐮𝐭𝐞 𝐨𝐟 𝐃𝐫𝐮𝐠 𝐀𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧 (𝐎𝐫𝐚𝐥, 𝐏𝐚𝐫𝐞𝐧𝐭𝐞𝐫𝐚𝐥, 𝐚𝐧𝐝 𝐎𝐭𝐡𝐞𝐫𝐬), 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥 (𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬, 𝐑𝐞𝐭𝐚𝐢𝐥 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬, 𝐄-𝐂𝐨𝐦𝐦𝐞𝐫𝐜𝐞), 𝐚𝐧𝐝 𝐑𝐞𝐠𝐢𝐨𝐧 𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟐". The global anti-rheumatics market size reached US$ 64.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 80.4 Billion by 2032, exhibiting a growth rate (CAGR) of 2.4% during 2024-2032.

Factors Affecting the Growth of Anti-Rheumatics Industry:

• Growing Number of Rheumatic Disease Patients

The increasing prevalence of rheumatic diseases globally contributes significantly to the expansion of this market. Rheumatic diseases, including rheumatoid arthritis, osteoarthritis, lupus, and gout, affect millions of individuals worldwide, with numbers continuing to rise due to factors such as aging populations and lifestyle changes. As a result, there is a growing demand for effective treatments to manage symptoms, alleviate pain, and improve the quality of life for individuals living with these conditions. This rising prevalence underscores the importance of innovation and investment in the development of new anti-rheumatic drugs and therapies to address the unmet needs of patients.

• Significant Technological Advancements:

The advancements in medical research and technology play a crucial role in driving growth in the anti-rheumatics market. The pharmaceutical industry continuously invests in research and development (R&D) efforts to discover novel drug targets, improve treatment efficacy, and minimize side effects associated with existing therapies. Breakthroughs in understanding the underlying mechanisms of rheumatic diseases, as well as the development of biologic drugs and targeted therapies, have revolutionized the management of these conditions. Additionally, the integration of precision medicine approaches, such as pharmacogenomics and biomarker identification, enables personalized treatment strategies tailored to individual patients, further driving market expansion.

• Expanding Geriatric Population:

The expanding geriatric population worldwide is a significant factor contributing to the growth of the anti-rheumatics market. Rheumatic diseases are more prevalent among older adults, and as the global population ages, the burden of these conditions is expected to increase. With a growing number of elderly individuals seeking medical care for rheumatic ailments, there is a rising demand for safe and effective anti-rheumatic treatments specifically tailored to the needs of this demographic. Consequently, pharmaceutical companies and healthcare providers are focusing on developing age-appropriate therapies and optimizing treatment protocols to address the unique challenges associated with managing rheumatic diseases in older patients. In conclusion, the anti-rheumatics market is driven by factors such as the increasing prevalence of rheumatic diseases, advancements in medical research and technology, and the expanding geriatric population.

Leading Companies Operating in the Global Anti-Rheumatics Industry:

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Biogen Inc.
• Bristol-Myers Squibb Company
• Celltrion Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Johnson & Johnsons
• Pfizer Inc.
• Sanofi SA

𝐅𝐨𝐫 𝐚𝐧 𝐢𝐧-𝐝𝐞𝐩𝐭𝐡 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬, 𝐲𝐨𝐮 𝐜𝐚𝐧 𝐫𝐞𝐟𝐞𝐫 𝐬𝐚𝐦𝐩𝐥𝐞 𝐜𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭: https://www.imarcgroup.com/anti-rheumatics-market/requestsample

Anti-Rheumatics Market Report Segmentation:

By Type:

• Prescription-based Drugs
• Over-the-Counter Drugs

Prescription-based drugs dominate the market due to the necessity for professional medical evaluation, diagnosis, and supervision, emphasizing the importance of regulated medication for managing rheumatic conditions effectively.

By Drug Class:

• Disease Modifying Anti-Rheumatics Drugs (DMARD's)
• Nonsteroidal Anti-Inflammatory Drugs (NSAID's)
• Corticosteroids
• Uric Acid Drugs
• Others

Disease modifying anti-rheumatics drugs (DMARD'S) holds maximum number of shares due to their pivotal role in slowing down disease progression and improving long-term outcomes for patients with rheumatic conditions.

By Route of Drug Administration:

• Oral
• Parenteral
• Others

Parenteral represents the largest segment due to its rapid onset of action, high bioavailability, and suitability for administering drugs to patients who cannot take medications orally.

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

Hospital pharmacies dominate the market due to their extensive reach, serving as primary sources of prescription medications and specialized treatments for patients receiving care within healthcare facilities.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐓𝐎𝐂: https://www.imarcgroup.com/anti-rheumatics-market

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Global Anti-Rheumatics Market Trends:

The increasing adoption of biologic therapies for rheumatic diseases is another factor driving the market. Biologic drugs, derived from living organisms, have demonstrated efficacy in treating conditions such as rheumatoid arthritis and psoriatic arthritis by targeting specific components of the immune system involved in inflammation. The growing acceptance and utilization of biologics as a preferred treatment option by physicians and patients alike propel market growth, as these therapies offer targeted relief with potentially fewer adverse effects compared to traditional disease-modifying anti-rheumatic drugs (DMARDs). Additionally, the expanding awareness and education campaigns about rheumatic diseases and available treatment options contribute to earlier diagnosis and intervention, driving demand for anti-rheumatic medications.

𝐍𝐨𝐭𝐞: 𝐈𝐟 𝐲𝐨𝐮 𝐧𝐞𝐞𝐝 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐭𝐡𝐚𝐭 𝐢𝐬 𝐧𝐨𝐭 𝐜𝐮𝐫𝐫𝐞𝐧𝐭𝐥𝐲 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐞 𝐬𝐜𝐨𝐩𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭, 𝐰𝐞 𝐰𝐢𝐥𝐥 𝐩𝐫𝐨𝐯𝐢𝐝𝐞 𝐢𝐭 𝐭𝐨 𝐲𝐨𝐮 𝐚𝐬 𝐚 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐭𝐡𝐞 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧.

𝐎𝐭𝐡𝐞𝐫 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐏𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐛𝐲 𝐈𝐌𝐀𝐑𝐂 𝐆𝐫𝐨𝐮𝐩 :

• https://www.imarcgroup.com/artifical-intelligence-healthcare-market
• https://www.imarcgroup.com/football-market
• https://www.imarcgroup.com/small-scale-lng-market
• https://www.imarcgroup.com/hernia-repair-market
• https://www.imarcgroup.com/disposable-face-mask-market

Contact Us:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 |United Kingdom: +44-753-713-2163

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

This release was published on openPR.